Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

Journal article

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

FUNCTIONAL GENOMICS INVESTIGATION OF THE ANKYLOSING SPONDYLITIS ASSOCIATED LOCUS RUNX3

Conference paper

Cohen C. et al, (2022), Annals of the rheumatic diseases, 81, 231 - 231

A FIRST IN DISEASE PHASE 2A TRIAL OF GRANULOCYTE MONOCYTE COLONY STIMULATING FACTOR NEUTRALISATION FOR AXIAL SPONDYLOARTHRITIS (NAMASTE STUDY)

Conference paper

Al-Mossawi MH. et al, (2021), Clinical and experimental rheumatology, 39, 1161 - 1161

COMPREHENSIVE EPIGENOMIC PROFILING REVEALS DISEASE-SPECIFIC CHROMATIN STATES IN ANKYLOSING SPONDYLITIS

Conference paper

Cohen CJ. et al, (2021), Clinical and experimental rheumatology, 39, 1155 - 1155

From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery.

Journal article

Nancy Z. et al, (2021), Front immunol, 12

NOVEL USE OF SPECIFIC DRUGS ATTENUATES THE PRO-INFLAMMATORY CYTOKINES IL-17A AND IFN-GAMMA

Conference paper

Ridley A. et al, (2021), Clinical and experimental rheumatology, 39, 1164 - 1164

Load More